Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure

1996 ◽  
Vol 51 (3-4) ◽  
pp. 269-272 ◽  
Author(s):  
M. Kentsch ◽  
W. Otter ◽  
C. Drummer ◽  
A. Nötges ◽  
R. Gerzer ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Neutral Endopeptidase ◽  
Haemodynamic Effects ◽  
Endopeptidase 24.11

Neutral Endopeptidase Inhibition: Augmented Atrial and Brain Natriuretic Peptide, Haemodynamic and Natriuretic Responses in Ovine Heart Failure

1996 ◽  
Vol 91 (3) ◽  
pp. 283-291 ◽  
Author(s):  
Miriam Tessa Rademaker ◽  
Christopher John Charles ◽  
Eric Arnold Espiner ◽  
Michael Gary Nicholls ◽  
Arthur Mark Richards ◽  
...  
Keyword(s):  
Heart Failure ◽  
Atrial Natriuretic Peptide ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Fold Increase ◽  
Neutral Endopeptidase ◽  
Haemodynamic Effects ◽  
Similar Extent ◽  
Endopeptidase 24.11 ◽  
Atrial Natriuretic

1. Atrial and brain natriuretic peptide are both circulating hormones subject to degradation by neutral endopeptidase 24.11. Whereas endogenous levels of atrial natriuretic peptide are increased by neutral endopeptidase inhibition in most pathophysiological states, the effect on brain natriuretic peptide and the influence of cardiac status is less clear. To further evaluate the role of neutral endopeptidase 24.11, we directly compared the responses of atrial and brain natriuretic peptide, together with the effects on other vasoactive hormones, haemodynamics and renal indices, to a neutral endopeptidase inhibitor, SCH32615, and a vehicle control in eight conscious sheep before and during pacing-induced heart failure. 2. In normal animals, SCH32615 significantly increased concentrations of plasma atrial natriuretic peptide (22±5 pmol/l compared with 14±2 pmol/l in control, 1.6-fold increase) and brain natriuretic peptide (6.5±1.2 pmol/l compared with 4.1±0.7 pmol/l in control, 1.6-fold increase), whereas in heart failure, plasma levels of atrial natriuretic peptide (306±38 pmol/l compared with 187±25 pmol/l in control, 1.6-fold increase) and brain natriuretic peptide (93±11 pmol/l compared with 55 ± 9 pmol/l in control, 1.7-fold increase) were elevated to a significantly greater absolute, but proportionately similar, extent. In both normal and heart-failed animals, SCH32615 induced reductions in mean arterial pressure and left atrial pressure and increases in haematocrit, plasma cGMP and endogenous creatinine clearance. However, only in heart failure did neutral endopeptidase inhibition induce a significant and marked natriuresis (> 10-fold increase) and diuresis (4-fold increase), together with suppression of renin activity and haemodynamic effects including decreased peripheral resistance and raised cardiac output. 3. In conclusion, neutral endopeptidase inhibition increases plasma concentrations of atrial and brain natriuretic peptide to a proportionately similar extent in both normal and heart-failed sheep. The striking natriuresis and diuresis and additional haemodynamic effects demonstrated in sheep with heart failure, where natriuretic peptide levels are elevated compared with normal sheep, supports the concept that neutral endopeptidase inhibition augments endogenous atrial and brain natriuretic peptide.

Haemodynamic Effects of Felodipine in Congestive Heart Failure

Drugs ◽  
1987 ◽  
Vol 34 (Supplement 3) ◽  
pp. 81-84 ◽  
Author(s):  
P. Held ◽  
K. Swedberg
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Haemodynamic Effects

scholarly journals Haemodynamic effects of dobutamine in patients with congestive heart failure receiving captopril.

Heart ◽  
1981 ◽  
Vol 46 (5) ◽  
pp. 528-530 ◽  
Author(s):  
H Ikram ◽  
A H Maslowski ◽  
M G Nicholls
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Haemodynamic Effects

Haemodynamic Effects of Long-Term Prazosin Therapy in Patients with Congestive Heart Failure

1980 ◽  
Vol 2 ◽  
pp. S427-S441 ◽  
Author(s):  
K. H. Kuck ◽  
P. Hanrath ◽  
A. Zenke ◽  
D. Mathey ◽  
W. Bleifeld
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Haemodynamic Effects

Effects of endothelin receptors ETA and ETB blockade on renal haemodynamics in normal rats and in rats with experimental congestive heart failure

2002 ◽  
Vol 103 (s2002) ◽  
pp. 245S-248S ◽  
Author(s):  
Zaid ABASSI ◽  
Bahaa FRANCIS ◽  
Jerry WESSALE ◽  
Elena OVCHARENKO ◽  
Joseph WINAVER ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Body Weight ◽  
Pressor Response ◽  
Haemodynamic Effects ◽  
Aortocaval Fistula ◽  
Renal Vasoconstriction ◽  
Mediated Effects ◽  
Vasodilatory Response ◽  
Renal Vascular

The present study examined the effects of two highly selective endothelin-1 (ET-1) receptor antagonists, ABT-627 (ETA blocker) and A-192621 (ETB blocker), on the systemic and renal haemodynamic effects of ET-1 in normal rats and in rats with experimental congestive heart failure (CHF) produced by aortocaval fistula. Intravenous injection of ET-1 (1.0nmol·kg-1 of body weight) to anaesthetized normal rats produced sustained decreases in renal blood flow (RBF) (assessed by ultrasonic flowmetry) and glomerular filtration rate (GFR), and significant increases in renal vascular resistance (RVR) and mean arterial pressure (MAP). Pretreatment with ABT-627 (1mg·h-1·kg-1 of body weight) abolished the pressor response to ET-1 without affecting the depressor phase, and significantly impaired the renal vasoconstriction. The systemic and renal vasoconstrictive effects of ET-1 in normal rats were significantly augmented by pretreatment with 3.0mg·h-1·kg-1 of A-192621. Baseline RBF and GFR in rats with CHF were reduced significantly compared with control rats, whereas RVR was elevated. The hypertensive effect of ET-1 was attenuated in rats with CHF. In the presence of ETA blockade, the pressor response to ET-1 was completely abolished in CHF rats. Furthermore, pretreatment with ABT-627 enhanced the recovery from ET-1- dependent vasoconstriction and remarkably reversed the ET-1-induced hypofiltration. Blockade of ETB receptors in rats with CHF further exposed the exaggerated ET-1-induced renal vasoconstriction. Our data demonstrate that experimental CHF is associated with altered responsiveness to ETA- and ETB-mediated systemic and renal effects of ET-1. Furthermore, in CHF, as in control rats, the ETB-mediated vasodilatory response may serve as an important compensatory counterbalance to the adverse ETA-mediated effects.

scholarly journals beta Blockade in congestive heart failure: persistent adverse haemodynamic effects during chronic treatment with subsequent doses

Heart ◽  
1997 ◽  
Vol 78 (5) ◽  
pp. 444-449 ◽  
Author(s):  
M. L Kukin ◽  
J. Kalman ◽  
M. M Mannino ◽  
C. Buchholz-Varley ◽  
O. Ocampo
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Chronic Treatment ◽  
Haemodynamic Effects ◽  
Beta Blockade
Sign in / Sign up

Export Citation Format

Share Document